Dialog Box


Imaging and molecular determinants of response to chemoradiation in glioblastoma

Professor Andrew Scott of the Olivia Newton-John Cancer Research Institute (La Trobe University School of Cancer Medicine) and Austin Health, with a world-class team of clinicians and scientists from around Australia, will work on improving prognosis and better predicting a glioblastoma patient’s likely response to therapy, along with their likelihood of resistance to treatment.

They aim to achieve this by utilising an imaging technique for detecting amino acid metabolism in brain tumours using Positron Emission Tomography, in a clinical trial of over 200 patients. This information can be used to guide treatment regimens with glioblastoma and hopes to promote personalised therapies to improve survival for those with brain cancer.

Prof Scott is one of the recipients of Cure Brain Cancer Foundation’s Innovation Grant, receiving funding of $200,000 over two years to fund this novel project that deviates from traditional research paradigms.  

Prof Scott stated, “The Cure Brain Cancer Foundation grant is enabling sophisticated image analysis of PET and MRI scans in patients participating in a multi-centre Medical Research Future Fund (MRFF) funded trial, which we hope will allow more accurate treatment and improve glioblastoma patient outcomes.”